Clinical trial discovery
Find Clinical Trials
Search studies by condition, treatment, location, eligibility, or trial identifier.
Showing 1–20 of 38 trials
Active filters
Clinical trials found
Published and searchable clinical trials
Searching for clinical trials...
NCT07003295
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- Emory University Hospital Midtown Atlanta, Georgia, United States
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
- Emory Saint Joseph's Hospital Atlanta, Georgia, United States
NCT06839053
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +25 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT06859008
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Disease Attributes, +39 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
NCT06675123
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Chronic Disease, Disease Attributes, +35 more
- Locations
-
- Mayo Clinic in Florida Jacksonville, Florida, United States
NCT04484012
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
NCT05910801
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Mayo Clinic in Rochester Rochester, Minnesota, United States
- M D Anderson Cancer Center Houston, Texas, United States
Not Yet Recruiting
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
NCT07673367
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States
Not Yet Recruiting
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT07578077
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
NCT04205409
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +46 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT02568553
- Conditions
- Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +53 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- UC San Diego Moores Cancer Center La Jolla, California, United States
- Los Angeles General Medical Center Los Angeles, California, United States
NCT04578600
- Conditions
- Chronic Disease, Disease Attributes, Hematologic Diseases, +39 more
- Locations
-
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
NCT03440567
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +14 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
NCT04872413
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Completed
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma
NCT03061188
- Conditions
- Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, +14 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
Completed
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
NCT02869633
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, Chronic Disease, Disease Attributes, +27 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Stanford Cancer Institute Palo Alto, California, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
- Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
NCT03219047
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT01865617
- Conditions
- CD19-Positive Neoplastic Cells Present, Chronic Disease, Disease Attributes, +32 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Completed
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
NCT02736617
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- OHSU Knight Cancer Institute Portland, Oregon, United States
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +38 more
- Locations
-
- Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
- Hackensack University Medical Center Hackensack, New Jersey, United States